264 related articles for article (PubMed ID: 9452347)
21. MAO-B inhibitors for the treatment of Parkinson's disease.
Mov Disord; 2002; 17 Suppl 4():S38-44. PubMed ID: 12211138
[No Abstract] [Full Text] [Related]
22. Selegiline and mortality in subjects with Parkinson's disease: a longitudinal community study.
Ben-Shlomo Y; Lees A;
Neurology; 2001 Jul; 57(2):369; author reply 369-70. PubMed ID: 11480425
[No Abstract] [Full Text] [Related]
23. A dose-ranging study of selegiline in patients with Parkinson's disease: effect of platelet monoamine oxidase activity.
Andreu N; Damase-Michel C; Senard JM; Rascol O; Montastruc JL
Mov Disord; 1997 May; 12(3):293-6. PubMed ID: 9159721
[TBL] [Abstract][Full Text] [Related]
24. Reexamination of the TEMPO Study.
Shults CW
Arch Neurol; 2005 Aug; 62(8):1320; author reply 1321. PubMed ID: 16087778
[No Abstract] [Full Text] [Related]
25. Simultaneous determination of MAO-A and -B activity following first time intake of an irreversible MAO-B inhibitor in patients with Parkinson's disease.
Müller T; Riederer P; Grünblatt E
J Neural Transm (Vienna); 2017 Jun; 124(6):745-748. PubMed ID: 28299453
[TBL] [Abstract][Full Text] [Related]
26. [Biochemical basis for using selective monoamine oxidase inhibitors in the treatment of Parkinson's disease. Critical contribution].
Amato L; Nava L; Rizzo M; Piccoli F
Riv Neurol; 1985; 55(1):46-52. PubMed ID: 3927468
[No Abstract] [Full Text] [Related]
27. Neuroprotection for Parkinson's disease: prospects and promises.
Olanow CW; Schapira AH; Agid Y
Ann Neurol; 2003; 53 Suppl 3():S1-2. PubMed ID: 12666093
[No Abstract] [Full Text] [Related]
28. Current status of selegiline as a neuroprotective agent in Parkinson's disease.
Olanow CW; Mytilineou C; Tatton W
Mov Disord; 1998; 13 Suppl 1():55-8. PubMed ID: 9613720
[No Abstract] [Full Text] [Related]
29. MAO-B inhibitors in Parkinson's disease.
Olanow CW
Adv Neurol; 1993; 60():666-71. PubMed ID: 8420207
[No Abstract] [Full Text] [Related]
30. Effect of adding selegiline to levodopa in early, mild Parkinson's disease. Evidence is insufficient to show that combined treatment increases mortality.
Aaltonen H; Kilkku O; Heinonen E; Mäki-Ikola O
BMJ; 1998 Dec; 317(7172):1586-7. PubMed ID: 9890764
[No Abstract] [Full Text] [Related]
31. Deprenyl--past and future. Proceedings of a symposium. Lake Starnberg, Bavaria, 1995.
J Neural Transm Suppl; 1996; 48():1-112. PubMed ID: 9102455
[No Abstract] [Full Text] [Related]
32. Selegiline's neuroprotective capacity revisited.
Riederer P; Lachenmayer L
J Neural Transm (Vienna); 2003 Nov; 110(11):1273-8. PubMed ID: 14628191
[No Abstract] [Full Text] [Related]
33. Rasagiline as a therapy for Parkinson's disease (PD).
Hermanowicz N
Am J Geriatr Pharmacother; 2007 Jun; 5(2):174-5; author reply 175-6. PubMed ID: 17719520
[No Abstract] [Full Text] [Related]
34. [Long-term treatment of Parkinson's disease patients with selegiline hydrochloride (FPF 1100): outcome of 5-year treatment].
Kondo T; Takubo H; Yokochi F; Okuma Y; Mizuno Y
No To Shinkei; 2002 Dec; 54(12):1041-8. PubMed ID: 12599519
[TBL] [Abstract][Full Text] [Related]
35. Deprenyl in Parkinson's disease.
Korczyn AD; Nisipeanu P
Ann Neurol; 1996 Aug; 40(2):268-9. PubMed ID: 8773617
[No Abstract] [Full Text] [Related]
36. Combination treatment with selective monoamine oxidase inhibitors and dopaminergic agonists in Parkinson's disease: biochemical and clinical observations.
Riederer P; Jellinger K; Danielczyk W; Seemann D; Ulm G; Reynolds GP; Birkmayer W; Koppel H
Adv Neurol; 1983; 37():159-76. PubMed ID: 6407285
[No Abstract] [Full Text] [Related]
37. A review of the mechanisms and role of monoamine oxidase inhibitors in Parkinson's disease.
Youdim MB; Riederer PF
Neurology; 2004 Oct; 63(7 Suppl 2):S32-5. PubMed ID: 15477584
[No Abstract] [Full Text] [Related]
38. Monoamine oxidase inhibitors--is it time to up the TEMPO?
Rascol O
Lancet Neurol; 2003 Mar; 2(3):142-3. PubMed ID: 12849233
[No Abstract] [Full Text] [Related]
39. Pregnancy in Parkinson's disease: a review of the literature and a case report.
Hagell P; Odin P; Vinge E
Mov Disord; 1998 Jan; 13(1):34-8. PubMed ID: 9452323
[TBL] [Abstract][Full Text] [Related]
40. Critical role of MAO inhibition in Parkinson's disease.
Knoll J
Adv Neurol; 1987; 45():107-10. PubMed ID: 3103382
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
